ENDRA Life Sciences Inc
NASDAQ:NDRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.8), the stock would be worth $4.74 (3% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.7 | $4.59 |
0%
|
| 3-Year Average | 1.8 | $4.74 |
+3%
|
| 5-Year Average | 337.3 | $903.93 |
+19 615%
|
| Industry Average | 1.9 | $5.12 |
+12%
|
| Country Average | 1.5 | $3.99 |
-13%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
5.4m USD | 1.7 | -0.8 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 10.9 | 56 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 2.2 | 25.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 3.1 | 36.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 1.5 | 22.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 2.3 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 4.7 | 43 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 1.2 | 18.2 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 14.4 | 41.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.2 | 23.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 4.4 | 20.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.9 |
| Median | 1.5 |
| 70th Percentile | 2.9 |
| Max | 566 432.7 |
Other Multiples
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
